CJC-1295 without DAC in Canada: A Research Guide to Modified GRF (1-29)

Why CJC-1295 without DAC deserves its own guide#

Canadian searches for "CJC-1295" usually arrive at pages that conflate two molecules into one product line. The reader sees a single label, a single price point, and a single set of claims, without being told whether the material is the long-acting albumin-binding analogue or the short-acting modified fragment. That ambiguity undermines research design, endpoint selection, and reproducibility.

This guide treats CJC-1295 without DAC — also called Modified GRF (1-29) or tetrasubstituted GRF (1-29) — as a distinct experimental tool. It is not a weaker version of CJC-1295 with DAC, nor is it a generic growth-hormone peptide. It is a short-acting GHRH-receptor agonist with a specific kinetic profile, and the useful research questions centre on why a short pulse might be preferable to sustained exposure.

The no-DAC form is particularly relevant to Canadian researchers who study GH-axis physiology, secretagogue synergy, and pulsatile endocrine signalling. Its brief half-life means it produces a discrete stimulus that can be sampled, washed out, and repeated within a single experimental day. The DAC version, by contrast, produces a multi-day signal that changes sampling schedules, washout periods, and interpretation frameworks. A researcher who confuses the two is not comparing doses; they are comparing different temporal paradigms.

This article does not provide dosing instructions, cycle design, injection protocols, or body-composition recommendations. It is written for researchers who need to separate pharmacokinetics from marketing, and who want to understand why the absence of a drug affinity complex is not a deficiency but a design feature.

What CJC-1295 without DAC is at the molecular level#

Native human growth-hormone-releasing hormone (GHRH or GRF) is a 44-amino-acid peptide produced in the hypothalamus. Its function is to stimulate somatotroph cells in the anterior pituitary to synthesise and secrete growth hormone. Its therapeutic and experimental limitation has always been brevity: native GHRH is rapidly inactivated by dipeptidyl peptidase IV (DPP-IV) and has a plasma half-life measured in minutes.

The 1-29 fragment as the bioactive core#

Early structure-activity work established that the N-terminal 29 residues of GHRH retain the full receptor-activating potency of the 44-amino-acid parent. The 1-29 fragment, sometimes called GRF(1-29), became the starting point for medicinal-chemistry optimisation. However, GRF(1-29) itself remains vulnerable to proteolytic cleavage, oxidation, and rapid renal filtration. It is too short-lived for most experimental and clinical applications.

The tetrasubstituted modifications#

The solution embodied in Modified GRF (1-29) is to introduce four specific amino-acid substitutions that increase metabolic stability without adding a large albumin-binding extension:

• D-Ala at position 2 — replaces the native L-Ala to reduce DPP-IV cleavage at the N terminus.
• Gln at position 8 — replaces Asn to improve resistance to deamidation and proteolysis.
• Ala at position 15 — replaces Gly to alter steric exposure and reduce susceptibility to cleavage.
• Leu at position 27 — replaces Met to reduce oxidative susceptibility at a residue that is otherwise prone to sulfoxide formation.

These four substitutions are shared with CJC-1295 with DAC. They are not the distinguishing feature between the two compounds. The distinguishing feature is what happens at the C terminus.

The absence of the drug affinity complex#

CJC-1295 without DAC terminates in an amidated C terminus without the Nε-maleimidopropionyl-lysine extension that defines the DAC form. That means it has no reactive moiety for albumin bioconjugation. After subcutaneous injection, the peptide circulates as a free molecule, susceptible to the same proteolytic and renal clearance mechanisms that limit the half-life of most short peptides.

The result is a half-life estimated in the range of 30 minutes to a few hours in human plasma — substantially longer than native GHRH, but orders of magnitude shorter than the albumin-bound DAC analogue. For researchers, this kinetic difference is the entire point. A compound that produces a discrete pulse can be used to study acute GH release, receptor desensitisation kinetics, and secretagogue synergy in ways that a sustained signal cannot.

Pharmacokinetics and the physiology of pulsatile GH release#

Growth hormone is secreted in pulses. The hypothalamus generates discrete bursts of GHRH — usually coordinated with ghrelin and somatostatin dynamics — and the pituitary responds with discrete GH secretory episodes. This pulsatility is not an incidental property of the axis. It is functionally important for receptor signalling, feedback regulation, and tissue-level IGF-1 generation.

Why sustained exposure changes the biology#

A long-acting GHRH analogue such as CJC-1295 with DAC produces sustained receptor occupancy. In some experimental contexts, sustained signalling is useful for studying chronic axis activation, IGF-1 maintenance, or growth-normalisation questions. In other contexts, sustained signalling disrupts the natural feedback architecture. The pituitary somatotroph may down-regulate GHRH receptors, alter GH pulse amplitude, or shift the balance between GH and somatostatin tone.

The short-acting modified fragment, by contrast, produces a pulse that more closely approximates the natural hypothalamic signal. A researcher who wants to model physiological GH pulsatility, study secretagogue synergy with precise timing, or avoid receptor down-regulation confounders may find the no-DAC form more appropriate.

Practical implications for sampling and protocol design#

A short half-life creates a narrow sampling window. Blood draws for GH measurement must be timed carefully relative to administration. Washout between doses is rapid, which allows same-subject crossover designs with shorter intervals. Repeated daily administrations can produce multiple discrete pulses, each with its own pharmacodynamic profile.

These characteristics make CJC-1295 without DAC a tool for acute endocrine studies rather than chronic maintenance studies. The research question should drive the choice: if the endpoint requires a sustained signal, the DAC form is the more direct pharmacological match. If the endpoint requires a pulsatile signal, the no-DAC form is closer to the physiological model.

The evidence map: three literatures, not one promise#

A serious review of Modified GRF (1-29) separates the evidence into three distinct layers.

Layer one: GHRH fragment pharmacology and medicinal chemistry#

The foundational literature for tetrasubstituted GRF(1-29) is embedded in the broader GHRH analogue programme. The Jette et al. 2005 paper that identified CJC-1295 as a long-acting albumin bioconjugate began with a panel of modified hGRF(1-29) analogues, including the tetrasubstituted core without the maleimide extension. The authors showed that the modified core retained GHRH-receptor activity in cultured rat anterior pituitary cells and that the substitutions improved stability relative to native GRF (Jette et al., 2005).

This layer is important because it establishes that the no-DAC form is not an inferior precursor. It is a pharmacologically active GHRH analogue in its own right, with a defined receptor target and a rational design history.

Layer two: animal endocrine and growth studies#

The murine growth-normalisation study commonly cited for CJC-1295 with DAC (Alba et al., 2006) used the albumin-binding analogue rather than the short-acting fragment. Researchers interested in the no-DAC form should therefore look to the broader GHRH analogue literature for comparable data. Early GHRH fragment studies in rats and swine demonstrated that modified GRF(1-29) analogues could stimulate acute GH release and support growth parameters when administered with appropriate frequency.

The practical implication is that the no-DAC form has less published pre-clinical literature specifically dedicated to it than the DAC form, because the DAC extension was the novel invention that attracted patent and publication interest. The no-DAC form is better understood as a well-characterised pharmacological intermediate: its properties are predictable from GHRH-receptor biology and DPP-IV pharmacology, even if it has not been the subject of large dedicated trials.

Layer three: human GH secretagogue and clinical endocrinology context#

Human data on short-acting GHRH fragments come from the clinical endocrinology literature rather than from peptide-supplier research. Sermorelin (unmodified GHRH 1-29) was approved in some jurisdictions for growth-hormone deficiency diagnosis and treatment. Tesamorelin (a different modified GHRH analogue) was approved for HIV-associated lipodystrophy. These clinical histories establish that GHRH-receptor agonism is a valid pharmacological strategy, but they do not make Modified GRF (1-29) an approved therapeutic in Canada.

For Canadian researchers, the relevant literature is the pharmacological principle — that a short-acting GHRH analogue can produce a discrete GH pulse — rather than any specific clinical trial of the no-DAC form. The compound should be treated as a research tool for modelling GHRH-receptor pharmacology and GH-axis dynamics, not as an authorised hormone-replacement therapy.

CJC-1295 without DAC versus CJC-1295 with DAC#

The most common source of confusion in the growth-hormone peptide category is the conflation of these two molecules. They share the same tetrasubstituted core but diverge at the C terminus in ways that change everything about exposure, receptor dynamics, and research design.

That distinction should shape every protocol decision. A study that intends to examine acute GH pulsatility, GHRH-GHRP synergy, or receptor desensitisation kinetics should not substitute the long-acting analogue for the short-acting fragment without redesigning the endpoints. Conversely, a study that intends to model sustained GHRH-receptor occupancy may find the DAC version appropriate, but only if the longer half-life is explicitly accounted for in sampling and washout schedules.

The molecular-weight difference is also analytically relevant. A supplier listing that does not specify DAC status cannot be verified by mass spectrometry alone, because the expected mass differs by approximately 280 Da. A credible certificate of analysis should state which form is present, and the chromatographic profile should be consistent with that identity.

How CJC-1295 without DAC compares with other growth-hormone peptides#

The growth-hormone peptide archive is strongest when each article does a different job. The pillar guide maps the whole category. The CJC-1295 with DAC article covers the long-acting analogue. The Sermorelin article covers the historical fragment. The Ipamorelin article covers selective GHSR framing. This article adds the missing short-acting GHRH analogue guide.

Comparison with Sermorelin#

Sermorelin is unmodified GHRH(1-29). It lacks the four substitutions that protect Modified GRF from DPP-IV and oxidation, and it has an even shorter half-life. Sermorelin is useful for protocols that require the most native-like GHRH-receptor pharmacology or that reference historical clinical literature. Modified GRF (1-29) is useful when slightly longer stability than Sermorelin is desired but multi-day exposure is not. They are not dose-equivalent, and they are not the same pharmacokinetic tool.

Comparison with Tesamorelin#

Tesamorelin is a clinical GHRH analogue with a trans-3-hexenoic acid modification on Tyr and a regulated history in HIV-associated lipodystrophy. Its sequence, modification, and evidence base are distinct from both the DAC and no-DAC forms of CJC-1295. Researchers should not treat Modified GRF (1-29) as a generic substitute for Tesamorelin in protocols that reference clinical endpoints.

Comparison with Ipamorelin, GHRP-2, GHRP-6, and Hexarelin#

These compounds belong in the GHRP/GHSR lane, not the GHRH-receptor lane. Ipamorelin is a selective GHSR agonist. GHRP-2 and GHRP-6 are older GHRP-family peptides with broader endocrine spillover. Hexarelin is a potent GHSR agonist with its own tissue-specific literature. Modified GRF (1-29) can be combined with any of these in research protocols that study dual-pathway synergy, but the combination is not automatically superior. The rationale must state why a discrete GHRH pulse plus a discrete GHSR stimulus is the correct model for the endpoint.

Comparison with MK-677#

MK-677 is a non-peptide oral ghrelin-receptor agonist with a sustained exposure profile measured in hours to days. It is not a GHRH analogue, it is not short-acting, and its pharmacokinetics are entirely different. The only similarity is that both compounds can influence the GH axis. Researchers should not conflate them in protocols or in supplier comparisons.

Research design implications of a short-acting GHRH analogue#

The choice between short-acting and long-acting GHRH analogues is not a question of potency. It is a question of experimental timing.

Sampling windows and acute pulse studies#

A short half-life creates a narrow pharmacodynamic window. Blood draws for GH measurement should be timed within minutes to an hour of administration, depending on the species and route. Missing the peak means missing the signal. A protocol using Modified GRF (1-29) should include more frequent sampling than a protocol using the DAC form, because the pulse is sharper and briefer.

Same-day washout and crossover designs#

Because clearance is rapid, same-subject crossover designs can use shorter washout periods. A researcher could administer the peptide in the morning, collect samples through the afternoon, and repeat the stimulus the next day without carryover confounding. The DAC form, with its multi-day half-life, requires washout periods measured in weeks for complete clearance, which limits crossover feasibility.

Synergy with GHRP-family peptides#

The classic research pairing of a GHRH analogue with a GHRP-family peptide relies on complementary receptor inputs: GHRH-receptor stimulation plus GHSR stimulation produce a larger GH pulse than either alone. This synergy was first described with native GHRH and GHRP-6, and it has been replicated with various analogues. Modified GRF (1-29) is well-suited to this paradigm because its short pulse can be precisely timed relative to the GHRP dose. A sustained GHRH signal from the DAC form changes the synergy dynamics, because the GHRH receptor is already occupied when the GHRP is administered.

Receptor desensitisation and down-regulation#

Sustained GHRH-receptor occupancy can lead to receptor down-regulation, reduced GH response, and altered feedback tone. A short-acting pulse may produce less desensitisation over repeated administrations, though this hypothesis depends on dose, frequency, species, and assay sensitivity. Researchers interested in receptor dynamics should consider whether the acute pulse model or the sustained exposure model is more appropriate for their specific question.

Sourcing and quality-control cautions for Canadian researchers#

Because the Canadian research peptide market frequently conflates the DAC and no-DAC forms, sourcing diligence is especially important for Modified GRF (1-29).

The DAC status ambiguity problem#

The first and most common red flag is a supplier page that lists only "CJC-1295" without specifying DAC status. The two molecules have different molecular weights, different HPLC profiles, and different research applications. A listing that does not declare which form is present is not suitable for serious research.

A credible listing for CJC-1295 without DAC should state:

• The expected molecular weight (~3367 Da for the free peptide, depending on salt form).
• The sequence identity: tetrasubstituted hGRF(1-29) with an amidated C terminus.
• Explicit "without DAC" or "no DAC" language in the product name and description.
• HPLC chromatogram showing purity for the specific lot.
• Mass spectrometry confirming the expected mass rather than the DAC mass.

Documentation red flags#

The second red flag is a COA that shows a mass consistent with the DAC form (~3647 Da) on a product labelled "without DAC." That mismatch suggests either mislabelling or contamination with the wrong analogue. Researchers should verify the mass against the declared identity before accepting the lot.

The third red flag is therapeutic or wellness marketing. Modified GRF (1-29) is not an approved drug in Canada for anti-ageing, body-composition improvement, or hormone replacement. Any supplier that implies clinical efficacy or provides dosing instructions for human use is operating outside research-use norms.

Shipping and stability considerations#

Canadian researchers should consider temperature exposure during shipping, especially in summer months. Lyophilised peptides are more thermostable than reconstituted solutions, but they should still remain cold during transit. Upon receipt, storage at -20°C is standard for long-term stability. Because the no-DAC form has no reactive maleimide group, stability is governed by standard peptide chemistry rather than conjugate reactivity, but moisture, oxidation, and repeated freeze-thaw cycles still degrade integrity.

Frequently asked questions#

How this guide fits the Northern Compound archive#

The growth-hormone category is strongest when each molecule has its own clear research identity. The pillar guide provides the map. The CJC-1295 with DAC article covers the long-acting albumin-binding analogue. The Sermorelin article covers the historical unmodified fragment. The Ipamorelin article covers selective GHSR framing. The Tesamorelin article covers a clinically recognisable GHRH analogue. The CJC-1295 and Ipamorelin blend article covers a common combined pair. This guide fills the remaining gap: the short-acting, pulsatile GHRH analogue that is frequently mentioned but rarely examined on its own terms.

That editorial role matters for search intent. A reader searching "CJC-1295 without DAC Canada" is often trying to understand whether the short-acting form is appropriate for their research question, or whether they have been sold the wrong molecule by a supplier that failed to distinguish the two. The responsible answer is a decision framework: understand the pharmacokinetic distinction, match the exposure profile to the endpoint, separate evidence from marketing, and verify the source.

Product links are useful only when they sit inside that framework. Readers can inspect CJC-1295 without DAC, CJC-1295 with DAC, Sermorelin, and Ipamorelin listings, but the article's conclusion is not "buy the shortest-acting one." The conclusion is that the right compound depends on receptor intent, exposure profile, endpoint design, and supplier documentation.

That is the standard Northern Compound should apply across the archive: useful enough for commercial search traffic, cautious enough for research-use-only compliance, and specific enough that a serious reader learns something beyond the product name.